You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 288 No. 13, October 2, 2002 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (38)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Rates of Spontaneous Reporting of Adverse Drug Reactions in France

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Spontaneous reporting remains the most used and efficient method of identifying new adverse drug reactions (ADRs) in the postmarketing phase.1 We assessed the magnitude of underreporting for serious ADRs in France by using data from 3 field pharmacoepidemiological studies.

Methods

The 3 studies we selected for analysis2-4 were published in peer-reviewed journals, conducted in France in 1997 through 1998, and based on a representative sample of the source population. Each study was intended to estimate the number of hospitalizations caused by drugs. Therefore, estimating the magnitude of underreporting was possible by comparing the reported ADRs to the number of cases spontaneously reported to the French pharmacovigilance system during the same period and within the same territory.


Results
In 1997, Lacoste-Roussillon et al2 studied the incidence of serious ADRs observed by a representative random sample of 200 general practitioners in the Aquitaine Region (southwestern France). In this prospective study, . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

An epistemology of patient safety research: a framework for study design and interpretation. Part 3. End points and measurement
Brown et al.
Qual Saf Health Care 2008;17:170-177.
ABSTRACT | FULL TEXT  

Recognizing Drug-Induced Liver Injury: Current Problems, Possible Solutions
Lee and Senior
Toxicol Pathol 2005;33:155-164.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.